Annotation Detail
Information
- Associated Genes
- NTRK3
- Associated Variants
- NTRK3 ETV6-NTRK3
- Associated Disease
- Pediatric B-lymphoblastic Leukemia
- Source Database
- CIViC Evidence
- Description
- In this manuscript, the authors describe the first genetically engineered mouse model of ETV6-NTRK3 ALL and report remarkable efficacy of TRK inhibitors, which induce complete suppression of leukemic cell proliferation when administered as a monotherapy. They also show in vivo efficacy of TRK inhibition in a PDX model of ETV6-NTRK3 ALL. TRK-targeting compounds including PLX7486 and larotrectinib are predicted to show efficacy in B-ALL with ETV6-NTRK3 fusion which accounts for approximately 1% of Ph-like B-ALL.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6930
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3985
- Variant URL
- https://civic.genome.wustl.edu/links/variants/801
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Pediatric B-lymphoblastic Leukemia
- Evidence Direction
- Supports
- Drug
- Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate,Larotrectinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 29880614
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate | Sensitivity | true |
| Larotrectinib | Sensitivity | true |